Quisque vel mauris ac
Maecenas eget lacus metus. Pellentesque accumsan faucibus enim
Duis a mauris euismod ex rhoncus tempus. Etiam mi ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
The latest version of GastroPlus®, GPX.2, is designed to change your PBPK/PBBM life. Join us for this webinar and judge for yourself. You’ll get a first look at game-changing new functionality that will revolutionize your PBPK/PBBM modeling. Our experts will introduce you to… • ACATPlus™, the extension of the industry-leading ACAT™ model for understanding local drug disposition in the gastrointestinal tract • AssessmentsPlus™, for efficiently building high-quality PBPK/PBBM models using embedded expert knowledge, including the option to enhance the advice with our finely-tuned large language model (LLM) • Distribution Dashboard, which provides mechanistic insight into the tissue binding in PBPK tissues and fitting the most relevant input parameter • Intramuscular and subcutaneous dosing, which have been incorporated into the GPX paradigm • Orchestrator, for automating GPX.2 workflows as well as extending functionality and plotting via R/Python • P-PSD™, for fitting dissolution data using a product particle size distribution to represent the surface area of drug substance available for dissolution • Virtual replicate BE functionality, enhanced to include full and semi-replicate designs commonly used in bioequivalence studies Attendees will have the opportunity to ask questions live during our Q&A. This is your chance to see the latest PBPK/PBBM software in action—register now to save your seat!
Wednesday, September 24, 2025
8:00 am - 9:00 am PDT
Vice President, PBPK Product Development
Simulations Plus
Neil Miller is the Vice President, PBPK Product Development at Simulations Plus, driving the development and application of physiologically based pharmacokinetic (PBPK) modeling software tools for the pharmaceutical, biotechnology, chemicals, and consumer goods industries.
Previously he was at GlaxoSmithKline for over 20 years gaining experience of working in the pharmaceutical industry.
His last position was as a Scientific Director within the Systems Modeling and Translational Biology group, leading a team of advanced PBPK specialists that provided end-to-end mechanistic modelling for drug discovery and development.
Key activities included predicting efficacious human doses at Candidate Selection (CS) and supporting drug product development with physiologically based biopharmaceutics modeling (PBBM). Neil’s early career was spent working in the drug metabolism and pharmacokinetic (DMPK) area.
He progressed from a bioanalytical scientist working in the lab generating DMPK data to a discovery DMPK project coordinator identifying quality molecules for CS.
He then discovered a passion for modeling and simulation, specializing in predicting human pharmacokinetics from preclinical data using both empirical and mechanistic based modeling approaches.
Over the last decade he has focused on the application of PBPK modeling in drug discovery and development and led the vision to have PBPK models in place for all compounds prior to in vivo studies in a “model first experiment later” paradigm.
He is the lead author of the impactful manuscript “Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies.” Neil has an MSc in Medicinal Chemistry & Drug Metabolism
from Loughborough University in the UK.
Besides his professional work and family life, Neil is a keep-fit enthusiast.
Senior Director, PBPK Services
Simulations Plus
Becky Graves is the Senior Director of PBPK Services at Simulations Plus where she works on consulting projects alongside mentoring scientists, providing mechanistic absorption and physiology-based pharmacokinetic (PBPK) models for the pharmaceutical industry.
She uses her 10+ years of modeling experience to develop mechanistic models in various pre-clinical species and human populations and to apply these to guide drug development at various stages of pre-clinical and clinical development. Prior to joining Simulations Plus she worked at
GlaxoSmithKline in positions of increasing seniority within Drug Metabolism and Pharmacokinetics (DMPK), progressing from bioanalytical work, through designing DMPK studies to providing the strategy for various drug discovery projects.
Finally, Becky moved into a team dedicated to providing end-to-end mechanistic modeling for drug discovery and development, including predicting efficacious human doses prior to First Time in Human studies and supporting drug product development with physiologically based biopharmaceutics
modelling (PBBM). Besides her professional work and family, Becky enjoys playing field hockey and spending time in the great outdoors.
Associate VP, Software Business Development (Moderator)
Simulations Plus
Peter Kilford is the Associate Vice President of Software Business Development for Simulations Plus.
Peter likes to find connections between our clients’ scientific needs and the best simulation approaches to support the next stage of the development process.
After obtaining his Ph.D.
at the University of Manchester studying the in vitro mechanisms of drug glucuronidation, Peter moved into various roles in the pharmaceutical industry.
Initially working as an in vitro metabolism study director, Peter then moved into a consulting role as a Drug Development Leader working with Global biotech clients to design and run first-in-human enabling packages of work.
Peter has also held positions in the bio-simulation industry and more recently as a business development director.
Throughout his career, Peter has supported programs from early discovery through to clinical development working on nonclinical studies and designing PBPK models to support drug development for a range of biotech and pharmaceutical clients.
This enables Peter to understand the diverse requirements of our clients and the need to move quickly to ensure that development goals can be met.
Speaker Title 4
Speaker Company 4Enter Text Here
Speaker Title 5
Speaker Company 5Enter Text Here
Speaker Title 6
Speaker Company 6Enter Text Here
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!